Wegovy Warnings: What Your Doctor Should Tell You Before Starting

Wegovy Warnings: What Your Doctor Should Tell You Before Starting

By Dr. Onikepe Adegbola, MD PhD

Wegovy works. The clinical data is strong — average weight loss of 15-17% of body weight in the STEP trials, meaningful improvements in cardiovascular risk, real changes in how patients relate to food. But every medication that produces significant physiological effects carries warnings that deserve attention, and Wegovy's warning list is longer than most patients realize.

I prescribe Wegovy at Mochi Health, and I've had these conversations hundreds of times. The pattern I see: patients arrive excited about the weight loss potential and understandably impatient to start. What gets lost in that enthusiasm are the warnings printed in 6-point font on a 40-page prescribing information document. So here's what actually matters — the Wegovy warnings that change how I prescribe, monitor, and counsel patients in real clinical practice.

The Boxed Warning: Thyroid C-Cell Tumors

This is the one that alarms patients most, and rightly so. Wegovy's prescribing information carries an FDA boxed warning — the most serious category — about thyroid C-cell tumors, including medullary thyroid carcinoma (MTC).

The evidence behind this warning comes primarily from animal studies. In rodents, semaglutide (Wegovy's active ingredient) caused thyroid C-cell tumors at clinically relevant doses. The duration and dose-dependency of exposure mattered — longer treatment and higher doses increased risk.

In humans, the picture is less clear. Large clinical trials haven't shown a statistically significant increase in MTC among semaglutide users. But MTC is rare to begin with, and clinical trials typically run 1-2 years. A cancer that takes 10-15 years to develop wouldn't show up in that timeframe.

How I handle this in practice: I screen every patient for personal or family history of MTC and Multiple Endocrine Neoplasia syndrome type 2 (MEN2) before prescribing. If either is present, Wegovy is contraindicated — no exceptions. For other patients, I check baseline calcitonin levels and monitor periodically, watching for symptoms like a neck mass, dysphagia, or persistent hoarseness.

Should this warning keep you from taking Wegovy? For most patients, no. But it should ensure your doctor actually checks your thyroid history rather than skipping the question.

Pancreatitis and Gallbladder Warnings

Acute pancreatitis has been reported in patients using Wegovy and other GLP-1 receptor agonists. The relationship is biologically plausible — GLP-1 affects pancreatic function directly, and rapid weight loss independently increases gallstone risk, which in turn raises pancreatitis risk.

Pancreatitis

In clinical trials, pancreatitis occurred in a small number of semaglutide-treated patients. Post-marketing reports have added cases. The symptoms to watch: severe abdominal pain that radiates to the back, often with nausea and vomiting. This isn't the garden-variety nausea that GLP-1 medications commonly cause — it's distinct and significantly more intense.

If pancreatitis is suspected, Wegovy should be discontinued immediately. I counsel patients on this explicitly: sudden severe upper abdominal pain that feels different from your usual GLP-1 side effects warrants emergency evaluation, not a wait-and-see approach.

Patients with a history of pancreatitis require especially careful risk-benefit discussion. I've prescribed Wegovy to patients with prior pancreatitis episodes, but only with close monitoring and a low threshold for discontinuation.

Gallbladder Disease

Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) are well-documented Wegovy warnings. In the STEP trials, gallbladder-related events occurred at roughly twice the rate in semaglutide groups compared to placebo.

The mechanism is straightforward. Rapid weight loss — particularly losing more than 1.5 kg per week — changes bile composition and promotes stone formation. Semaglutide-induced weight loss can be brisk, especially in the first few months at higher doses.

I tell patients: if you develop right upper quadrant pain, especially after eating fatty foods, don't dismiss it as another GLP-1 GI complaint. Get an ultrasound. Gallbladder disease caught early is manageable. Missed, it can progress to cholecystitis or pancreatitis.

Kidney and Cardiovascular Wegovy Warnings

Acute Kidney Injury

Wegovy warnings include risk of acute kidney injury and worsening of chronic kidney disease. The mechanism isn't the drug attacking the kidneys directly — it's dehydration. GLP-1 medications cause nausea, vomiting, and diarrhea. Patients who become dehydrated from these GI effects and don't replenish fluids can develop prerenal acute kidney injury.

I've seen this happen twice in my practice. Both times, patients were early in their titration, experiencing significant nausea and vomiting, drinking less because they felt sick, and didn't recognize the warning signs until their creatinine spiked. Both recovered fully once hydrated, but the episodes were avoidable.

My protocol: baseline kidney function labs before starting. Repeat at 3 months and then every 6 months. Aggressive hydration counseling — aim for at least 64 ounces of water daily, more if you're having GI symptoms. Patients with pre-existing kidney disease get more frequent monitoring.

Heart Rate Increases

Semaglutide causes a modest increase in resting heart rate — typically 2-4 beats per minute. For most patients, this is clinically insignificant. But for patients with underlying cardiac arrhythmias, heart failure, or resting tachycardia, even small increases warrant attention.

The paradox: Wegovy has demonstrated cardiovascular benefit in the SELECT trial, with a 20% reduction in major adverse cardiovascular events. So the drug appears to protect the heart overall while modestly increasing heart rate. I monitor heart rate at follow-up visits and ask about palpitations, especially in patients with cardiac history.

Mental Health Warnings

In 2024, the FDA required updated labeling for all GLP-1 receptor agonists regarding suicidal ideation and behavior. This followed reports to the FDA's Adverse Event Reporting System (FAERS) from patients experiencing new or worsening depression, anxiety, and suicidal thoughts while taking these medications.

The data here is complicated. Large observational studies, including a study of over 200,000 patients published in JAMA Internal Medicine, have not found an overall increased risk of suicidal behavior with GLP-1 agonists compared to other weight loss treatments. Some studies have actually suggested a protective effect.

But individual cases exist, and they're real. I take this warning seriously by screening for depression and anxiety before prescribing, asking specifically about mood changes at every follow-up, and being particularly cautious with patients who have a psychiatric history.

Weight loss itself can trigger complex emotional responses. Patients may experience identity shifts, relationship changes, or unexpected grief about their previous relationship with food. These aren't necessarily drug side effects — they're psychological consequences of rapid body change that deserve clinical attention regardless.

GI Warnings and Practical Management

The most common Wegovy warnings relate to the GI tract: nausea (44% in clinical trials), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%). These aren't just statistics — they affect real patients' quality of life and adherence.

Most GI side effects are worst during dose titration and improve over weeks. But "improve" doesn't always mean "resolve." I have patients who manage persistent low-grade nausea and altered bowel habits throughout their treatment course.

Practical management strategies I recommend:

• Eat smaller meals. Your stomach is emptying slower on Wegovy. Eating the same volume you used to eat will cause distress.
• Prioritize protein. You need adequate protein to preserve muscle mass during weight loss. A gut-gentle option like GLP-1 Companion Whey Protein makes hitting your protein targets possible when appetite is minimal.
• Support digestion actively. A GLP-1 Digestive Enzyme Companion helps break down food that's sitting in a slower-moving GI tract, reducing bloating and discomfort.
• Cover nutritional gaps. Eating less means absorbing fewer micronutrients. A GLP-1 Daily Nutrition Companion addresses the vitamin and mineral deficiencies that caloric restriction creates.
• Stay hydrated. 64+ ounces of water daily. Non-negotiable.

These aren't supplements replacing medical care. They're the nutritional foundation that makes GLP-1 therapy safer and more tolerable. Casa de Sante GLP-1 supplements were specifically formulated for patients dealing with these exact challenges — low-FODMAP, gut-gentle, physician-developed.

Who Should Not Take Wegovy

Beyond the warnings, there are absolute contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Known hypersensitivity to semaglutide or any excipient
• Pregnancy (Wegovy should be discontinued at least 2 months before planned conception due to its long half-life)

Relative contraindications — situations where I prescribe with extra caution — include history of pancreatitis, severe gastroparesis, active gallbladder disease, significant renal impairment, and untreated or unstable psychiatric conditions.

The conversation I always have: Wegovy warnings don't mean the drug is dangerous for most people. They mean it's a real medication with real effects on your body, and treating it as such — with proper screening, monitoring, and support — determines whether your experience is a success story or a cautionary tale.

Frequently Asked Questions

What is the most serious Wegovy warning?

The boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma. This is the FDA's highest-level warning. While the evidence comes primarily from animal studies, patients with personal or family history of MTC or MEN2 should never take Wegovy.

Can Wegovy cause depression or suicidal thoughts?

The FDA added labeling about suicidal ideation in 2024 following post-marketing reports. Large population studies haven't confirmed an overall increased risk, but individual cases have been reported. Patients should report any new or worsening mood changes to their provider immediately.

Should I worry about pancreatitis on Wegovy?

Pancreatitis is a documented risk, though uncommon. Watch for severe upper abdominal pain radiating to the back — this is distinct from typical GLP-1 nausea. Seek emergency care if suspected. Risk is elevated in patients with prior pancreatitis or heavy alcohol use.

Are Wegovy warnings different from Ozempic warnings?

The warnings are nearly identical because both contain semaglutide. Wegovy is dosed higher (up to 2.4mg weekly vs. Ozempic's 2mg maximum), which may modestly increase the frequency of dose-dependent side effects like GI symptoms. The same boxed warning applies to both.

How often should I get labs while taking Wegovy?

I recommend baseline labs (comprehensive metabolic panel, A1c, lipid panel, thyroid function) before starting, repeat at 3 months, then every 6 months during treatment. Patients with kidney disease or diabetes may need more frequent monitoring. Your prescribing physician should establish a monitoring schedule.